Drug Index

Sodium Stibogluconate

Mechanism :

Exact mechanism of action is unknown. Proposed mechanisms include conversion to trivalent form of antimony that affects glucose metabolism, fatty acid beta oxidation, and adenosine triphosphate (ATP) formation.

Indication :

  • Leishmaniasis: cutaneous, mucosal and visceral leishmaniasis.

Contraindications :

Hypersensitivity, Significant renal impairment; breast-feeding.

Dosing :

20 mg/kg/day. Duration of therapy is 20 days for cutaneous leishmaniasis and 28 days for mucosal and visceral leishmaniasis.

Adverse Effect :

Diarrhea, nausea, vomiting, Flattened T wave, inversion T wave, prolonged Q-T interval, Headache, lethargy, malaise, Abdominal pain, anorexia, increased serum lipase and amylase, depressed bone marrow (transient), Arthralgia, myalgia.

Interaction :

Amphotericin B: May enhance the cardiotoxic effect of Sodium Stibogluconate.
QT-prolonging Agents like Antidepressants, Antipsychotics, Class 1C Anti-Arrhythmic, Kinase Inhibitors, Quinolone Antibiotics: May enhance the QTc-prolonging effect of Sodium Stibogluconate.

Hepatic Dose :

Avoid use.
02/13/2024 15:58:34 Sodium Stibogluconate
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0